MPB et squetch,
Anyone for a game of gin rummy?
I had to come back after I saw you guys had degenerated to talking about telecommunications on the thread. Somebody had to make honest men out of you.
Actually sorry for the hiatus, I've been very busy making money which has not been that easy in this sector the last few weeks so I had to go out and do it the old fashioned way...consulting <g>.
As for Predictive Medicines group, my crystal ball says 1Q98. I suspect the deal may be on the cusp as I write but if it doesn't go out this week, why lose the PR in the second half of December. BTW, MLNM has undergone an internal reorganization to streamline operations, has either of you heard anything public on it?
>>Back to topic, I found a little article on this pharmacogenomics area, the subtitle is "New, hot - but there is no it - yet" Cute, eh.
Says genomics companies are looking to access the expertises of CROs (Contract Research Organizations), HMOs and hospital centers in order to make p-genomics work. P-genomics deals in 96/97 include those by Abbott and Frenh company Genset; the SmithKline-Incyte deal, the Spectra acquisition by Glaxo, deals by AFFX with Glaxo and with Oncormed, etc. Other firms listed as thinking that they can make a business in p-genomics are GENE, MLNM, and SQNA, and start-ups like Genaissance Pharmaceuticals and Nova Molecular. Another interesting start-up is Rosetta Inpharmatics out of Lee Hood's lab in U. Washington (Hood's technology was key for Applied Biosystems, now a unit of Perkin Elmer).<<
Where'd you find this article, MPB, I'd like to dig it up.
Whose deal is it?
biowa |
